On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There are still more than 30 days left, almost 5 weeks. Let’s give patience a shot for a change. How about it? The cycle will break the silence within the next 2 weeks. There is no point in PRing anything until after Labor Day when all the big money and big players are back from holiday.
Again, read the dam thread.
That isn’t what I said at all. Read the dam thread. The .75 was from the rascally rabbit, and I merely pointed out what it would mean for me as I have added at the extreme lows while many have griped and complained trying to discourage new investors. At the start of the year my cost basis was 0 for a couple of hundred thousand shares. It’s now around .20.
FWIW I’m looking for $2-$5 depending on news this next cycle.
No I didn’t and you know I didn’t say I’d be happy. I outlined what .75 would mean to Leo and his shares. I said it would be 5 time my current cost basis. That’s all I said.
That’s a complete lie. I already told you the exact opposite. The only thing true is I am level headed. Nothing like your making stuff up.
Are you kidding? You think my post conveys losing hope? Unlike so many others here, I’m looking forward to the rewards of patience in accumulation and September.
I was speaking to a .75 buyout. Nothing more, nothing less, and a million or so either way is incidental to $39 million.
Of course, your numbers seem to not benefit or affect me in any substantial way, but, yes, I’m only one investor though having a shitload of shares.
Leo Ehrlich approximate stock and option ownership as of June 1 2018:
~34 million shares
https://backend.otcmarkets.com/otcapi/company/financial-report/196140/content
+ ~20 million options @ .11 per share
=================
~55 million shares fully diluted
.75 a share = ~$41 million - ~$2 million cost of options
A nice $39 million retirement, granted.
For me that would yield ~$380k, a nice 5x total current investment. Disappointing, but I’d take it.
A little fuzzy in the math, but I’m too lazy to sweat the minutiae...
Are you suggesting Leo owns or controls a total of 280 million shares ($210 million divided by .75). Wow that’s a lot of shares for a CEO to gift himself.
I think the post is guilty of fuzzy math. Very fuzzy math.
Please post a link where Leo said this.
“P results [will] be released in Q1 2018”
Currently not in Hawaii. So, I’m not in that Lane. (Snicker, pun intended) Some friends and family are in the possible path, so I’m still concerned. Hoping that storm doesn’t turn right at Kauai, like Iniki did in September 1992.
Go IPIX!
Because a BTD adds a lot of value to any new drug license.
Also, waiting for Prurisol bottom line to see what other options are available before finalizing any agreement.
Elementary, community college, Small Business Administration 101.
B-OM isn’t on a shelf. It is very active. They are now waiting for a BTD Approval while currently formulating and packaging. Even without the BTD someone will be interested in the only effective treatment for OM that delays onset and severity, reduces time of severity and prevents severe OM in over 40 percent of all head and neck cancer patents.
If the Phase 2b Prurisol is weak, there are still a strong B-OM and a B-UP to license. So you are wrong about their being out of business. Someone will want one, both or all of Brilacidin.
As discussed earlier in the week, the lease automatically extends on the 30th September, unless one party or the other informs that it won’t be extending. So, unless someone knows that Leo or the property manager said there was no extension SIX MONTHS AGO, IPIX is in the space another 5 years.
Some of the CDAs have been in place for more than a year, so, yes, another 5 weeks is more than enough time to finalize a deal for B-OM, Prurisol, all of Brilacidin or a company buyout.
Identifying a more responsive subset of patients is not cherry picking. It’s identifying more responsive subsets for future trial design. Nothing more and nothing less.
Yes, that word does appear often, mine did, but I didn’t see it in the IPIX 2013 agreement.
Your argument without further consideration is that the are misleading. As I’ve pointed out, they are not. What’s more, what you and others characterize as less than stellar results were much much better than that. When examined using historical placebo responses, 20% better jumps to a respectable 40% better. The very high placebo response is easily explained by its high dropout rate due to earlier and severe OM onset. Even with a 20% onset, B-OM was much better than merely mediocre since there is nothing g else currently available other than ice cubes. Also one had to dismiss a >1 point improvement for all Brilacidin patients to make the argument.
Once again a post ignores the facts of subgroup analysis and mischaracterizes it as misdirection. Performing subgroup reporting identifies which patients the next study should focus and for which patients the treatment might not benefit. This is what the FDA wants to see in both an accelerated pathway approval as well as the next clinical protocol. I’m great full that Leo shred this with us, and yes he probably needed to release the subgroup data to point out that for some patients Brilacidin rinse appeared to be most responsive, beyond the 20% improvement over the placebo of the general study population.
That’s not what it says. I thought like you at first then I reread it several times. The lease automatically extends UNLESS there is notification by either NOT to extend. As far as we know, there has been no notification, so the lease automatically extends on 30 September.
But, perhaps there is a typo in your paraphrasing?
I agreed.
Paragraph 2 of Lease Extension #1 says that there will be automatic 5 year extensions of the lease UNLESS the Lessor or Lessee provides notice between 6 and 12 months prior to the expiration of the current lease period indicating that they DO NOT intend to extend. It ends with this statement: "Time is of the essence.”
Accepting the accuracy of your quote, the lease will automatically extend on September 30. So, there is no “out-on-their-asses clause,” unless Leo or the lessor gave notice. Interesting, even better than I had speculated. Thanks.
Nonsense. The FDA is looking for the fullest data analysis, including subsets. Advancing from Phase 2 to Phase 2/3, 3 or 4, they use those subsets to determine potential, not absolute, unquestionable efficacy. That is your standard and not the FDA’s.
The April May data was a valid subset and reflects how data points are analyzed. The FDA expects those kinds of subsets. Moreover, those sunsets should be included in an application for BTD. Moreover, the Sunday’s will be included in the next trial application whether for phase 3 or 4, and it indicates which subsets of patients might benefit most.
No, don’t recall seeing a copy in a filing. I’m just assuming it is pretty much standard and boilerplate. Management is always happy to work with long time lease holders, providing the accommodation is reasonable. Even if management wants IPIX out, it could take months in the legal system to force vacating.
I mean what I said: 1) the end of the lease does not mean IPIX will not have offices or a lab the day after September 30. Posters keep implying this and it’s just not true. 2) September 30 is the last day of the quarter. Any milestones reached and reported ahead of that hard date gets fully reported in the quarterly report and not just entry as a disclosure of interim events. 3) I believe that the choosing of September 30 has to do with it being almost a month after the end of executive summer vacations as well as the end of the fiscal quarter. The closing of the lease period is incidental to the end of the quarter, but not without meaning.
As previously pointed out, the lease expiring is not an “out-on-their-asses” hard time line. It’s simply the expiration of the binding agreement at which point IPIX can revert to month-to-month or until a notice to vacate from the property management. So, as far as September 30 goes, lease wise it’s a big nothing event, though the date of expiration does not lack significance.
However, that date is the end of the first fiscal quarter. It’s also four weeks after the unofficial end of summer and vacation season, four weeks past Labor Day. I think those two events are not simply coincidental and adding the expiring of the lease, the date becomes even less arbitrary.
Anyone who has held a business lease knows that there is first a clause that refers to reverting to month to month at the expiration of the lease. Then there is a clause that covers timely notice to vacate premises. And, there is often a clause discussing terms and timing for lease renewal. I’m certain that Leo has discussed with the property manager/owner all options for vacating, extending or renewing the lease depending on the outcome of the next 6 weeks.
I've already got that covered, albeit not a Citation Mustang. At my age, the Mooney is more than quick enough, and less challenging. 7.50 a share supports one in perpetuity, or decertification, whichever comes first.
Are you suggesting Leo is a Mini-Musk? I’ll gladly take a Mini-Musk move at $7.50.
As LR pointed out, 20 CDAs could be 4 BPs. It might even be 2 with 10 CDAs each, though I doubt that. But, we do know it’s at least 2, and most probably more.
For novices to biopharma, against the noise from Trolleville, CDAs restrict and limit in both directions of confidentiality. A CDA limits both parties’ public discussions and disclosures. The absence of evidence is never evidence of failure. It is nothing more than evidence of an absence of disclosure for whatever reasons.
I owned 2 restaurants before returning to university for advanced degrees.
Not all businesses are Monday through Friday. Preclinical testing and clinical trials don’t stop because it’s 5:00 on a Friday. Business and other deals are often struck on golf courses. Ever go to a Sunday picnic, start talking business, and agree to get together over lunch to talk some more?
What in any of the post to which you are responding makes you assume I think Leo could drop all 3 milestones on a Sunday? On any Sunday? All at once on the last day? All I’m saying is the business of working on, drafting and signing agreements is not the same as trading days and is not limited by non-holidays Monday through Fridays.
I think it’s important not to confuse business days with trading days. Trading days depends on Monday thru Friday except holidays. Is there US trading on Labor Day? On the other hand, business days include days one does business or can do business. Many restaurants do business Sundays thru Saturdays, as do malls and many department stores. My dentist only conducts business on Tuesdays, Thursdays and Saturdays. Rosh Hashanah and Yom Kippur are non-business holidays for some. But, much behind the doors business gets conducted by those honoring such holy days.
As for IPIX, Leo et al have worked through weekends and holidays when needed. So, again, please, there are 53 potential business days remaining, not 38.
To all waiting for the B-OM report I promised for Friday, I’m still in an Internet black hole where very little can escape. It may take the rest of the weekend. I hope to have it compiled and completed before Monday. I’m currently at an international airport that receives 3 international flights a week. The flight out is delayed several hours, and I’ve already been here for 5 hours. Connectivity comes and g
First, clinical trial results only become material events after some form of disclosure to non-insiders. Results then become tradable information that impacts (or can impact) company valuation. The company must disclose material information to everyone at the same time. To the question of releasing to shareholders first, generally public releases are to everyone and not just shareholders.
To the general issue of public release before a release to a party in negotiations, shareholders and the general public have no higher or less right to potential material information. However, depending on what’s in the CDA binding confidentiality, a potential partner or licensee can receive non public information ahead of shareholders and general public. The CDA can bind all parties to non disclosure and in effect can make all under a CDA insiders.
Anyone thinking differently please add or correct.
The Loaded Boat is on first, The Train is leaving second, with the Volcano ready to explode from 3rd. The Rocket is up, looks to the moon and points. The bowler is on the pitch and there’s the toss to the wicket. A miss, air ball!
Now, it’s first and goal on the 1 yard line. It’s a fake kick by The Cynic, and The Optimist goalie easily takes the ball tossing it to The Confused middle hitter who leaps high into the air spiking the shuttlecock off the head of The Trash-Talking point guard. Overloaded, at center, leaps at the basket for a slam dunk, but it’s off the left upright settling back onto the pitch.
The Rocket is still up. There’s another bowl on its way. It’s looking like a head pin split, but Leo, who looked completely out of position, makes a great play against The Evil MM and it’s.... [cliffhanger]
Stay tuned for more IPIX game day play, but first this....